Aurinia Pharmaceuticals Inc. Operating Cash Flow
Aurinia Pharmaceuticals Inc. (AUPH) reported Operating Cash Flow of $85.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $52.57M, a 18.82% increase year-over-year.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $32.56M, a 2404.62% increase year-over-year.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $45.67M, a 51.65% increase year-over-year.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $44.45M, a 161.02% increase year-over-year.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2025 was $135.66M, a 205.62% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2024 was $44.39M.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$33.46M.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$79.53M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $52.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $85.13M 10-Q · filed 2026-08-06 | $130.79M derived: sum of 3 quarters · filed 2026-08-06 | $175.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $32.56M 10-Q · filed 2026-05-07 | $78.23M derived: sum of 2 quarters · filed 2026-05-07 | $122.68M derived: sum of 3 quarters · filed 2026-05-07 | $166.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $45.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $90.12M derived: sum of 2 quarters · filed 2026-02-26 | $134.36M derived: sum of 3 quarters · filed 2026-08-06 | $135.66M 10-K · filed 2026-02-26 |
| 2025-09-30 | $44.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $88.69M derived: sum of 2 quarters · filed 2026-08-06 | $89.99M 10-Q · filed 2025-11-04 | $120.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $44.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $45.54M 10-Q · filed 2026-08-06 | $75.66M derived: sum of 3 quarters · filed 2026-08-06 | $92.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.30M 10-Q · filed 2026-05-07 | $31.41M derived: sum of 2 quarters · filed 2026-05-07 | $48.44M derived: sum of 3 quarters · filed 2026-05-07 | $64.29M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.14M derived: sum of 2 quarters · filed 2026-02-26 | $62.99M derived: sum of 3 quarters · filed 2026-02-26 | $44.39M 10-K · filed 2026-02-26 |
| 2024-09-30 | $17.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $32.87M derived: sum of 2 quarters · filed 2025-11-04 | $14.27M 10-Q · filed 2025-11-04 | $28.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $15.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$2.75M 10-Q · filed 2025-07-31 | $11.56M derived: sum of 3 quarters · filed 2026-02-26 | -$1.72M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$18.60M 10-Q · filed 2025-05-12 | -$4.29M derived: sum of 2 quarters · filed 2026-02-26 | -$17.56M derived: sum of 3 quarters · filed 2026-02-26 | -$20.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $14.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.03M derived: sum of 2 quarters · filed 2026-02-26 | -$1.79M derived: sum of 3 quarters · filed 2026-02-26 | -$33.46M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$13.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$16.10M derived: sum of 2 quarters · filed 2024-11-07 | -$47.77M 10-Q · filed 2024-11-07 | -$37.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$2.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$34.50M 10-Q · filed 2024-08-01 | -$24.05M derived: sum of 3 quarters · filed 2025-02-27 | -$39.41M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$31.67M 10-Q · filed 2024-05-02 | -$21.22M derived: sum of 2 quarters · filed 2025-02-27 | -$36.58M derived: sum of 3 quarters · filed 2025-02-27 | -$64.45M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$4.91M derived: sum of 2 quarters · filed 2025-02-27 | -$32.78M derived: sum of 3 quarters · filed 2025-02-27 | -$79.53M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$15.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$43.23M derived: sum of 2 quarters · filed 2023-11-02 | -$89.98M 10-Q · filed 2023-11-02 | -$115.90M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$27.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$74.62M 10-Q · filed 2023-08-03 | -$100.54M derived: sum of 3 quarters · filed 2024-02-15 | -$140.79M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$46.75M 10-Q · filed 2023-05-04 | -$72.67M derived: sum of 2 quarters · filed 2024-02-15 | -$112.92M derived: sum of 3 quarters · filed 2024-02-15 | -$150.90M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$25.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$66.17M derived: sum of 2 quarters · filed 2024-02-15 | -$104.15M derived: sum of 3 quarters · filed 2024-02-15 | -$157.69M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$40.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$78.23M derived: sum of 2 quarters · filed 2022-11-03 | -$131.77M 10-Q · filed 2022-11-03 | -$128.57M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$37.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$91.52M 10-Q · filed 2022-08-04 | -$88.32M derived: sum of 3 quarters · filed 2023-02-28 | -$116.73M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$53.54M 10-Q · filed 2022-05-10 | -$50.34M derived: sum of 2 quarters · filed 2023-02-28 | -$78.75M derived: sum of 3 quarters · filed 2023-02-28 | -$100.79M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$25.21M derived: sum of 2 quarters · filed 2023-02-28 | -$47.25M derived: sum of 3 quarters · filed 2023-02-28 | -$69.86M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$28.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$50.45M derived: sum of 2 quarters · filed 2021-11-03 | -$73.06M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$22.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$44.65M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$22.61M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$63.59M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | -$51.61M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |